Although the canonical Wnt/beta-catenin pathway is upregulated in ALS, riluzole, an enhancer of the canonical Wnt signaling, is classically prescribed in this disease in humans. This evidence concerns the gene CTNNB1 and amyotrophic lateral sclerosis.